WAO Guideline for the Management of Hereditary Angioedema

Abstract

: Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and appropriate therapy are often unknown or not available for physicians and other health care providers. For this reason we convened a group of specialists that focus upon HAE from around the world to develop not only a consensus on diagnosis and management of HAE, but to also provide evidence based grades, strength of evidence and classification for the consensus. Since both consensus and evidence grading were adhered to the document meets criteria as a guideline. The outcome of the guideline is to improve diagnosis and management of patients with HAE throughout the world and to help initiate uniform care and availability of therapies to all with the diagnosis no matter where the residence of the individual with HAE exists.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 141

1. 1.

   Brozek JL Akl EA Alonso-Coello P Lang D Jaeschke R Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventionsAllergy2009 5669677

   Not in our library10.1111/j.1398-9995.2009.01973.x

2. 2.

   Cicardi M Bork K Caballero T Craig T Li HH Longhurst H Reshef A Zuraw B Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working GroupAllergy2012 5147157

   Not in our library10.1111/j.1398-9995.2011.02751.x

3. 3.

   Munch EP Weeke B Non-hereditary angioedema treated with tranexamic acid. A 6-month placebo controlled trial with follow-up 4 years laterAllergy1985 59297

   Not in our library10.1111/j.1398-9995.1985.tb02666.x

4. 4.

   Lewis JH Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disordersAliment Pharmacol Ther1991 5suppl 11524

   Not in our library10.1111/j.1365-2036.1991.tb00745.x

5. 5.

   Gluszko P Undas A Amenta S Szczeklik A Schmaier AH Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitorJ Lab Clin Med1994 5232240

   Not in our library

6. 6.

   Cicardi M Mannucci PM Castelli R Rumi MG Agostoni A Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrateTransfusion1995 5209212

   Not in our library10.1046/j.1537-2995.1995.35395184276.x

7. 7.

   Waytes AT Rosen FS Frank MM Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrateN Engl J Med1996 516301634

   Not in our library10.1056/nejm199606203342503

8. 8.

   Cicardi M Castelli R Zingale LC Agostoni A Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patientsJ Allergy Clin Immunol1997 5194196

   Not in our library10.1016/s0091-6749(97)70095-2

9. 9.

   Goring HD Bork K Späth PJ Bauer R Ziemer A Hintner H Wüthrich B Hereditary angioedema in the German-speaking region [in German]Hautarzt1998 5114122

   Not in our library10.1007/s001050050710

10. 10.

    Kunschak M Engl W Maritsch F Rosen FS Eder G Zerlauth G Schwarz HP A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedemaTransfusion1998 5540549

    Not in our library10.1046/j.1537-2995.1998.38698326333.x

11. 11.

    Farkas H Gyeney L Gidófalvy E Füst G Varga L The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental proceduresJ Oral Maxillofac Surg1999 5404408

    Not in our library10.1016/s0278-2391(99)90280-x

12. 12.

    Bork K Barnstedt SE Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedemaArch Intern Med2001 5714718

    Not in our library10.1001/archinte.161.5.714

13. 13.

    Gompels MM Lock RJ Gidófalvy E Füst G Varga L A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiencyJ Clin Pathol2002 5145147

    Not in our library10.1136/jcp.55.2.145

14. 14.

    Weiler JM Quinn SA Woodworth GG Brown DD Layton TA Maves KK Does heparin prophylaxis prevent exacerbations of hereditary angioedema?J Allergy Clin Immunol2002 59951000

    Not in our library10.1067/mai.2002.124892

15. 15.

    Szeplaki G Varga L Valentin S Kleiber M Karádi I Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedemaJ Allergy Clin Immunol2005 5864869

    Not in our library10.1016/j.jaci.2004.12.1130

16. 16.

    van Doorn MB Burggraaf J van Dam T Eerenberg A Levi M A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedemaJ Allergy Clin Immunol2005 5876883

    Not in our library10.1016/j.jaci.2005.05.019

17. 17.

    Bas M Bier H Greve J Kojda G Hoffmann TK Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibantAllergy2006 514901492

    Not in our library10.1111/j.1398-9995.2006.01197.x

18. 18.

    Bork K Frank J Grundt B Schlattmann P Nussberger J Kreuz W Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)J Allergy Clin Immunol2007 514971503

    Not in our library10.1016/j.jaci.2007.02.012

19. 19.

    Ott HW Mattle V Hadziomerovic D Licht P Döinghaus K Treatment of hereditary angioneurotic oedema (HANE) with tiboloneClin Endocrinol (Oxf)2007 5180184

    Not in our library10.1111/j.1365-2265.2006.02704.x

20. 20.

    Schneider L Lumry W Vegh A Williams AH Schmalbach T Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitorJ Allergy Clin Immunol2007 5416422

    Not in our library10.1016/j.jaci.2007.04.028

21. 21.

    Varga L Biro A Széplaki G Tóth L Horváth A Füst G Farkas H Anti-cholesterol antibody levels in hereditary angioedemaJ Cell Mol Med2007 513771383

    Not in our library10.1111/j.1582-4934.2007.00124.x

22. 22.

    Visy B Fust G Bygum A Bork K Longhurst H Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedemaHelicobacter2007 5251257

    Not in our library10.1111/j.1523-5378.2007.00501.x

23. 23.

    Birjmohun RS Kees Hovingh G Stroes ES Hofstra JJ Dallinga-Thie GM Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedemaClin Ther2008 523142323

    Not in our library10.1016/j.clinthera.2008.12.021

24. 24.

    Cedzynski M Madalinski K Gregorek H Swierzko AS Nowicka E Possible disease-modifying factors: the mannan-binding lectin pathway and infections in hereditary angioedema of children and adultsArch Immunol Ther Exp (Warsz)2008 56975

    Not in our library10.1007/s00005-008-0004-7

25. 25.

    Szegedi R Szeplaki G Varga L Prohászka Z Széplaki Z Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patientsAtherosclerosis2008 5184191

    Not in our library10.1016/j.atherosclerosis.2007.09.025

26. 26.

    Craig TJ Levy RJ Wasserman RL Bewtra AK Hurewitz D Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksJ Allergy Clin Immunol2009 5801808

    Not in our library10.1016/j.jaci.2009.07.017

27. 27.

    Kreuz W Martinez-Saguer I Aygören-Pürsün E Rusicke E Heller C Klingebiel T C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxisTransfusion2009 519871995

    Not in our library10.1111/j.1537-2995.2009.02230.x

28. 28.

    Bas M Greve J Stelter K Bier H Stark T Hoffmann TK Kojda G Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case seriesAnn Emerg Med2010 5278282

    Not in our library10.1016/j.annemergmed.2010.03.032

29. 29.

    Bernstein JA Ritchie B Levy RJ Wasserman RL Bewtra AK Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacksAnn Allergy Asthma Immunol2010 5149154

    Not in our library10.1016/j.anai.2010.06.005

30. 30.

    Cicardi M Banerji A Bracho F Malbrán A Rosenkranz B Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedemaN Engl J Med2010 5532541

    Not in our library10.1056/nejmoa0906393

31. 31.

    Cicardi M Levy RJ McNeil DL Li HH Sheffer AL Ecallantide for the treatment of acute attacks in hereditary angioedemaN Engl J Med2010 5523531

    Not in our library10.1056/nejmoa0905079

32. 32.

    Craig TJ Wasserman RL Levy RJ Bewtra AK Schneider L Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedemaJ Clin Immunol2010 5823829

    Not in our library10.1007/s10875-010-9442-1

33. 33.

    Levy RJ Lumry WR McNeil DL Li HH Campion M Horn PT Pullman WE EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedemaAnn Allergy Asthma Immunol2010 5523529

    Not in our library10.1016/j.anai.2010.04.012

34. 34.

    Zuraw B Cicardi M Levy RJ Nuijens JH Relan A Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedemaJ Allergy Clin Immunol2010 5821827.e814

    Not in our library10.1016/j.jaci.2010.07.021

35. 35.

    Zuraw BL Busse PJ White M Jacobs J Lumry W Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedemaN Engl J Med2010 5513522

    Not in our library10.1056/nejmoa0805538

36. 36.

    Bissler JJ Donaldson VH Davis AE Contiguous deletion and duplication mutations resulting in type 1 hereditary angioneurotic edemaHum Genet1994 5265269

    Not in our library10.1007/bf00212020

37. 37.

    Zhang Y Dipple KM Vilain E Huang BL Finlayson G AluY insertion (IVS4-52ins316alu) in the glycerol kinase gene from an individual with benign glycerol kinase deficiencyHum Mutat2000 5316323

    Not in our library10.1002/(sici)1098-1004(200004)15:4<316::aid-humu3>3.0.co;2-9

38. 38.

    Bowen T Hebert J Ritchie B Burnham J MacSween M Management of hereditary angioedema: a Canadian approachTransfus Apher Sci2003 5205214

    Not in our library10.1016/j.transci.2003.08.009

39. 39.

    Bowen T Cicardi M Farkas H Bork K Kreuz W Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary AngioedemaJ Allergy Clin Immunol2004 5629637

    Not in our library10.1016/j.jaci.2004.06.043

40. 40.

    Bracho FA Hereditary angioedemaCurr Opin Hematol2005 5493498

    Not in our library10.1097/01.moo.0000179805.57486.4e

Cited by papers we hold 7

• The International/Canadian Hereditary Angioedema Guideline · 2019
  Corrected
• Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies · 2018
  No notice
• Outcomes of long term treatments of type I hereditary angioedema in a Turkish family · 2017
  Not checked
• Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey · 2016
  Not checked
• The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency · 2014
  No notice
• Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe · 2013
  No notice
• Hereditary angioedema: how to approach it at the emergency department?
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.